PeruTuberculosis profile
Population  2014 31 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.2 (1.8–2.7) 7.2 (5.7–8.8)
Mortality (HIV+TB only) 0.25 (0.18–0.34) 0.81 (0.57–1.1)
Prevalence  (includes HIV+TB) 49 (23–84) 158 (75–272)
Incidence  (includes HIV+TB) 37 (30–45) 120 (98–145)
Incidence (HIV+TB only) 2.5 (2–3.1) 8.1 (6.5–9.9)
         
Case detection, all forms (%) 81 (67–99)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 5.3 (4.9–5.7) 20 (19–22)
MDR-TB cases among notified pulmonary
TB cases
1 200 (1 100–1 300) 800 (750–860)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 17 823   2 128
Pulmonary, clinically diagnosed 4 204   366
Extrapulmonary 5 348   139
       
Total new and relapse 30 008    
Previously treated, excluding relapses 1 453    
Total cases notified 31 461    
Among 27 375 new cases:
1 559 (6%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 12 949 (73%) 3 375 (83%) 21 148
Laboratory-confirmed RR-/MDR-TB cases     1 463
Patients started on MDR-TB treatment ***     1 671
TB/HIV 2014 Number (%)
TB patients with known HIV status 23 280 (74)
HIV-positive TB patients 1 385 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 578 (42)
HIV-positive TB patients on antiretroviral therapy (ART) 913 (66)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 1 126  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (79) 17 265
Previously treated cases registered in 2013 (59) 2 802
HIV-positive TB cases, all types, registered in 2013 (57) 1 016
RR-/MDR-TB cases started on second-line treatment in 2012 (60) 1 122
XDR-TB cases started on second-line treatment in 2012 (38) 34
Laboratories 2014  
Smear (per 100 000 population) 4.8
Culture (per 5 million population) 8.1
Drug susceptibility testing (per 5 million population) 1.1
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 84
% Funded domestically 96%
% Funded internationally 2%
% Unfunded 2%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-10-01 Data: www.who.int/tb/data